The United States are likely to approve important developments in the covid-19 vaccine. Advisers to US FDA recommended the Pfizer vaccine for children ages 5 to 11.
The vaccine may be available to the younger age group starting next week. The FDA is not required to follow the advice of its outside experts, but it generally does. There were 17 votes in favor and one abstention.
The United States Is Likely to Approve the Pfizer Vaccine for Children Between the Ages of 5 and 11:
Washington: an expert panel voted overwhelmingly Tuesday to recommend that the u.S. Food and drug administration approve the Pfizer Inc. And BioNTech see covid-19 vaccine for children ages 5 to 11, saying the benefits of the vaccine outweigh the benefits. A permit for this age group would be an important policy step in approaching the nearly 28 million children. Most of whom return to school for personal learning, for vaccination. The vaccine may be available to the younger age group starting next week.
- If the FDA approves the vaccine, an advisory board from the u.S. Centers for disease control and prevention will meet next week to discuss the vaccine. The CDC director makes the last call.
- Children with severe illness or who have died from covid-19 are rarer than adults. But unvaccinated children are problematic and more likely to be infected. Because they are more susceptible to the delta coronavirus.
- More than 500 children die from covid-19 in the United States, according to data from the American academy of pediatrics.
The United States Is Likely to Approve Use of This Vaccine Prevents Death:
This group was ranked 8th in infant mortality last year, said Dr. Amanda Korn, CDC pediatrician, and voting committee member. The use of this vaccine prevents death, intensive care unit hospitalization, and long-term adverse consequences for children. Several other countries, including China, Cuba, and the United Arab Emirates, have so far approved the covid-19 vaccine for children under that age. In the United States, only 57% of the population are fully vaccinated.
Lagging behind other countries like the United Kingdom and France. However, the level of vaccinated infants may be below. In the United States, vaccination rates for adolescents aged 12 to 15 are about 47% higher than in other age groups. In May, the world health organization called on developing countries to review their childhood immunization programs and donate the COVAX -19 vaccine to the poorest countries.
Pfizer and BioNTech are seeking approval for a low-dose vaccine of 10 micrograms in infants, compared with 30 micrograms for children over 12 years of age. Shooting is allowed from may at the age of 12-15 after a leave for more than 16 years in December. The two companies said the vaccine was 90.7% effective against coronavirus in clinical trials involving children between the ages of 5 and 11.
The counselor paid particular attention to the rate of heart inflammation called Myocarditis associated with the Pfizer/BioNTech and Modena vaccines, especially in young men. In most of the scenarios analyzed, covid-19-avoided hospitalizations were avoided with Myocarditis if the number of cases of Myocarditis in the younger age group was found to be similar to the number of cases between 12 and 15 years of age. Of hospitalizations. Said the staff inspector. In a document prepared before Tuesday’s meeting.
Eric Rubin, the Editor of the New England Journal of Medicine, Said:
Moderna released data from its clinical trials in children between the ages of 6 and 11 on Monday and said it would soon seek regulatory approval for this age group. It is unclear when we regulators will take this into account. The company is still awaiting a response to an application filed in June for the use of the vaccine in children aged 12 to 17 years. By the end of the year, Pfizer said data from clinical trials in younger children between the ages of 2 and 4 may be available.